Literature DB >> 27989769

Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.

Brian B Liau1, Cem Sievers1, Laura K Donohue1, Shawn M Gillespie1, William A Flavahan1, Tyler E Miller2, Andrew S Venteicher3, Christine H Hebert1, Christopher D Carey4, Scott J Rodig4, Sarah J Shareef1, Fadi J Najm1, Peter van Galen1, Hiroaki Wakimoto5, Daniel P Cahill5, Jeremy N Rich2, Jon C Aster4, Mario L Suvà1, Anoop P Patel6, Bradley E Bernstein7.   

Abstract

Glioblastoma, the most common and aggressive malignant brain tumor, is propagated by stem-like cancer cells refractory to existing therapies. Understanding the molecular mechanisms that control glioblastoma stem cell (GSC) proliferation and drug resistance may reveal opportunities for therapeutic interventions. Here we show that GSCs can reversibly transition to a slow-cycling, persistent state in response to targeted kinase inhibitors. In this state, GSCs upregulate primitive developmental programs and are dependent upon Notch signaling. This transition is accompanied by widespread redistribution of repressive histone methylation. Accordingly, persister GSCs upregulate, and are dependent on, the histone demethylases KDM6A/B. Slow-cycling cells with high Notch activity and histone demethylase expression are present in primary glioblastomas before treatment, potentially contributing to relapse. Our findings illustrate how cancer cells may hijack aspects of native developmental programs for deranged proliferation, adaptation, and tolerance. They also suggest strategies for eliminating refractory tumor cells by targeting epigenetic and developmental pathways.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  KDM6A/B; Notch; cancer; chromatin; drug resistance; epigenetics; glioblastoma; histone demethylases; stem cell

Mesh:

Substances:

Year:  2016        PMID: 27989769      PMCID: PMC5291795          DOI: 10.1016/j.stem.2016.11.003

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  75 in total

1.  Cooperative transcriptional activation by the neurogenic basic helix-loop-helix protein MASH1 and members of the myocyte enhancer factor-2 (MEF2) family.

Authors:  B L Black; K L Ligon; Y Zhang; E N Olson
Journal:  J Biol Chem       Date:  1996-10-25       Impact factor: 5.157

2.  Essential roles of Notch signaling in maintenance of neural stem cells in developing and adult brains.

Authors:  Itaru Imayoshi; Masayuki Sakamoto; Masahiro Yamaguchi; Kensaku Mori; Ryoichiro Kageyama
Journal:  J Neurosci       Date:  2010-03-03       Impact factor: 6.167

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Authors:  Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

5.  Mastermind critically regulates Notch-mediated lymphoid cell fate decisions.

Authors:  Ivan Maillard; Andrew P Weng; Andrea C Carpenter; Carlos G Rodriguez; Hong Sai; Lanwei Xu; David Allman; Jon C Aster; Warren S Pear
Journal:  Blood       Date:  2004-06-08       Impact factor: 22.113

6.  SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity.

Authors:  Rosaria Maria Rita Gangemi; Fabrizio Griffero; Daniela Marubbi; Marzia Perera; Maria Cristina Capra; Paolo Malatesta; Gian Luigi Ravetti; Gian Luigi Zona; Antonio Daga; Giorgio Corte
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

7.  Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.

Authors:  Ran Xu; Fumiko Shimizu; Koos Hovinga; Kathryn Beal; Sasan Karimi; Leif Droms; Kyung K Peck; Philip Gutin; J Bryan Iorgulescu; Thomas Kaley; Lisa DeAngelis; Elena Pentsova; Craig Nolan; Christian Grommes; Timothy Chan; Dylan Bobrow; Adilia Hormigo; Justin R Cross; Nian Wu; Naoko Takebe; Katherine Panageas; Percy Ivy; Jeffrey G Supko; Viviane Tabar; Antonio Omuro
Journal:  Clin Cancer Res       Date:  2016-05-06       Impact factor: 12.531

8.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome.

Authors:  Bo Li; Colin N Dewey
Journal:  BMC Bioinformatics       Date:  2011-08-04       Impact factor: 3.307

9.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Authors:  Laurens Kruidenier; Chun-wa Chung; Zhongjun Cheng; John Liddle; KaHing Che; Gerard Joberty; Marcus Bantscheff; Chas Bountra; Angela Bridges; Hawa Diallo; Dirk Eberhard; Sue Hutchinson; Emma Jones; Roy Katso; Melanie Leveridge; Palwinder K Mander; Julie Mosley; Cesar Ramirez-Molina; Paul Rowland; Christopher J Schofield; Robert J Sheppard; Julia E Smith; Catherine Swales; Robert Tanner; Pamela Thomas; Anthony Tumber; Gerard Drewes; Udo Oppermann; Dinshaw J Patel; Kevin Lee; David M Wilson
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

10.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  147 in total

1.  Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma.

Authors:  Wen-Bin Yang; Che-Chia Hsu; Tsung-I Hsu; Jing-Ping Liou; Kwang-Yu Chang; Pin-Yuan Chen; Jr-Jiun Liu; Shung-Tai Yang; Jia-Yi Wang; Shiu-Hwa Yeh; Ruei-Ming Chen; Wen-Chang Chang; Jian-Ying Chuang
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

Review 2.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

3.  FHL3 links cell growth and self-renewal by modulating SOX4 in glioma.

Authors:  Wei Han; Peishan Hu; Fan Wu; Shanshan Wang; Yan Hu; Shanshan Li; Tao Jiang; Boqin Qiang; Xiaozhong Peng
Journal:  Cell Death Differ       Date:  2018-06-28       Impact factor: 15.828

4.  Drug persistence - from antibiotics to cancer therapies.

Authors:  Karl Kochanowski; Leanna Morinishi; Steven Altschuler; Lani Wu
Journal:  Curr Opin Syst Biol       Date:  2018-03-31

Review 5.  Brain Tumor Stem Cells Remain in Play.

Authors:  Luis F Parada; Peter B Dirks; Robert J Wechsler-Reya
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

6.  Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition.

Authors:  Molly Gale; Zongzhi Z Liu; Yao Li; Jian Cao; Marissa A Holmbeck; Meiling Zhang; Sabine M Lang; Lizhen Wu; Mariana Do Carmo; Swati Gupta; Keisuke Aoshima; Michael P DiGiovanna; David F Stern; David L Rimm; Gerald S Shadel; Xiang Chen; Qin Yan
Journal:  Cancer Res       Date:  2019-11-05       Impact factor: 12.701

7.  Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.

Authors:  Maithili P Dalvi; Lei Wang; Rui Zhong; Rahul K Kollipara; Hyunsil Park; Juan Bayo; Paul Yenerall; Yunyun Zhou; Brenda C Timmons; Jaime Rodriguez-Canales; Carmen Behrens; Barbara Mino; Pamela Villalobos; Edwin R Parra; Milind Suraokar; Apar Pataer; Stephen G Swisher; Neda Kalhor; Natarajan V Bhanu; Benjamin A Garcia; John V Heymach; Kevin Coombes; Yang Xie; Luc Girard; Adi F Gazdar; Ralf Kittler; Ignacio I Wistuba; John D Minna; Elisabeth D Martinez
Journal:  Cell Rep       Date:  2017-05-23       Impact factor: 9.423

Review 8.  Epigenetic plasticity and the hallmarks of cancer.

Authors:  William A Flavahan; Elizabeth Gaskell; Bradley E Bernstein
Journal:  Science       Date:  2017-07-21       Impact factor: 47.728

9.  Lineage Plasticity in Cancer Progression and Treatment.

Authors:  Clémentine Le Magnen; Michael M Shen; Cory Abate-Shen
Journal:  Annu Rev Cancer Biol       Date:  2017-12-01

10.  Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype.

Authors:  Tong Xu; Hong-Tao Li; Jenny Wei; Meng Li; Tien-Chan Hsieh; Yi-Tsung Lu; Ranjani Lakshminarasimhan; Rong Xu; Emmanuelle Hodara; Gareth Morrison; Hemant Gujar; Suhn Kyong Rhie; Kimberly Siegmund; Gangning Liang; Amir Goldkorn
Journal:  Int J Cancer       Date:  2020-02-22       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.